@GothamGirl_1 GothamGirl

GothamGirl posts on X about $sgmo, scale, what is, in the the most. They currently have [-----] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

[--] Week [-----] -5.40%
[--] Month [-----] +319%
[--] Months [------] +479%
[--] Year [------] +32,807%

Mentions: [--] #

[--] Months [--] +69%
[--] Year [--] +3,400%

Followers: [-----] #

[--] Week [--] +2.10%
[--] Month [--] +17%
[--] Months [--] +269%
[--] Year [--] +2,300%

CreatorRank: [---------] #

Social Influence

Social category influence finance stocks technology brands exchanges currencies

Social topic influence $sgmo #6, scale, what is, in the, bio, fail, pay, bp, market, pain

Top accounts mentioned or mentioned by @sangamotx @sandymacrae23 @johnmarkels @meangenebio @francaole @zinselmeyerb @soerenberlin @gothamgirl1 @biotechanalysst @schoolyardps7 @bambossie81 @jewcypickle @riddakilla76 @prtj1 @geneinvesting @thecryptomaze @tristatephil @steve72354669 @jota5571189851 @thetreatment2

Top assets mentioned uniQure N.V. (QURE) CRISPR Therapeutics AG (CRSP) Alphabet Inc Class A (GOOGL) Novartis AG (NVS) Uber Technologies, Inc. (UBER)

Top Social Posts

Top posts by engagements in the last [--] hours

"@Thetreatment2 @ZinselmeyerB @andrewpaleogos $SGMO Form 4s for Sandy and other executives will be filed today or tomorrow as a reminder to shareholders that executives continue to receive free monthly options while the company teeters on the brink of bankruptcy. #clownshow #criminalmismanagement"
X Link 2025-03-25T14:27Z [--] followers, [---] engagements

"@SangamoTx $SGMO @sandymacrae23 @JohnMarkels Can Sangamo afford to send anyone to present at ASGCT There is this"
X Link 2025-04-30T19:36Z [--] followers, [---] engagements

"@jewcypickle @RiddaKilla76 $SGMO Couldn't it signal that they are moving Fabry forward without a partner and are confident they can continue to dilute shareholders to fund it"
X Link 2025-07-23T00:47Z [--] followers, [---] engagements

"@jewcypickle @RiddaKilla76 $SGMO It still does not add up for me. You speculate they are making these expensive moves/ decisions because they have secured a partner but if they have secured a partner wouldn't they have to (and want to) disclose it"
X Link 2025-07-23T02:20Z [--] followers, [---] engagements

"$SGMO @sandymacrae23 @johnmarkels @sangamotx Will you screw shareholders with more dilution like you did with last quarter's earnings call Will you announce a Fabry partnership agreement or sale or continue to claim you are in the "final" stages of negotiations #NoFabryPartner"
X Link 2025-07-31T22:23Z [--] followers, [---] engagements

"$SGMO @sangamotx @SandyMacrae @JohnMarkels Sangamo used to announce their Qtly earning's date on X in advance but not this Q. Maybe they realize they will receive only negative comments since they screwed shareholders w/ dilution on last Q's earnings call. Still #NoFabryPartner"
X Link 2025-08-06T14:52Z [--] followers, [---] engagements

"@SangamoTx $SGMO @sandymacrae23 @JohnMarkels On the earnings call I heard Sandy say wrt Fabry "I am very pleased with the pace of partnership negotiations." Really Sandy Exactly how many "potential partners" are still in active discussions with Sangamo #NoFabryPartner #Fraud"
X Link 2025-08-07T21:59Z [--] followers, [---] engagements

"@prtj1 @sangamotx @sandymacrae23 @johnmarkels Hi Patrick Trucchio of HCW. On the Sangamo earnings call why didn't you ask what is holding up the Fabry partnership or how many potential partners Will you lower your $10 PT given the ATM dilution and failure to partner Fabry"
X Link 2025-08-07T22:06Z [--] followers, [--] engagements

"@Franca_ole @SangamoTx @sandymacrae23 @JohnMarkels $SGMO They are negotiating from a position of weakness not withstanding the excellent data. They acknowledged as much on the earnings call - their cash position has made it difficult to negotiate. They have to be reasonable if they want to survive. And they need a new CFO"
X Link 2025-08-08T19:57Z [--] followers, [---] engagements

"@Franca_ole @SangamoTx @sandymacrae23 @JohnMarkels $SGMO Does "placing approved shares on the market" mean more dilution Selling non-neuro assets brings in non-dilutive funding which should be the ONLY acceptable funding option for shareholders who have suffered enough under this clown-show management team"
X Link 2025-08-08T20:12Z [--] followers, [---] engagements

"@Franca_ole @SangamoTx @sandymacrae23 @JohnMarkels $SGMO This is exactly the point - insolvency SHOULD NOT BE imminent. It would not be if they sell (rather than partner) non-neuro assets"
X Link 2025-08-08T20:46Z [--] followers, [---] engagements

"@JungleJorge2 @SangamoTx @sandymacrae23 @JohnMarkels He made the statement on May 8th then delayed the earnings call and diluted shareholders on May 12th [--] business days later"
X Link 2025-08-14T14:09Z [--] followers, [--] engagements

"$SGMO @sangamotx @sandymacrae23 @johnmarkels Mr. Rauer probably negotiated compensation in the event of insolvency &/or a sh/tload of options. Sangamo have no negotiating leverage with potential employees or partners because they have driven the company to the edge of bankruptcy. @GothamGirl_1 @SangamoTx @sandymacrae23 @JohnMarkels $SGMO not some second-tier interns signed the follow-up agreement. Mr. Rauer clearly asked about the outlookdoesnt seem like the type who cant find another opportunity. Well see how it all plays out in the coming days and weeks. @GothamGirl_1 @SangamoTx"
X Link 2025-09-07T20:33Z [--] followers, [----] engagements

"$SGMO I survived [--] large mergers on Wall St. Not sure how it works with bios but with banks they let go a ton of people ahead of the merger so they can say later that the merger did not result in many lay-offs. This might be a one-off but if more "resignations" follow great. $SGMO buyout coming imho. CFO leaving as expected in that type of situation. $SGMO buyout coming imho. CFO leaving as expected in that type of situation"
X Link 2025-09-11T21:49Z [--] followers, [---] engagements

"@CryptoFrogMaxi @meangenebio How long have you been following Sangamo She was promoted when the last CFO left. She has been in over her head the entire time. This was not the right role for her. I am sure she is happy to leave a stressful situation but also sure she was not up to the task"
X Link 2025-09-11T23:26Z [--] followers, [--] engagements

"$SGMO I don't understand the details behind the filing cadence but in [----] insiders filed Form 4s in [--] out of [--] months. So far in [----] they have filed in [--] of [--] months. Also a different mix of people file each month. $SGMO I noticed that they didnt file their normal end of month SEC Form [--] last month. They did that like clockwork until last month. $SGMO I noticed that they didnt file their normal end of month SEC Form [--] last month. They did that like clockwork until last month"
X Link 2025-10-01T23:50Z [--] followers, [---] engagements

"$SGMO @SangamoTx @sandymacrae23 @johnmarkels Except that is was not "shared tonight." It was shared [--] months ago at a conference and nobody (Sangamo management biotech analysts reporters.) thought it noteworthy but you say is is worth $4-5 in SGMO stock price today. This Car-Tregs data $SGMO shared tonight is a breakthrough and its a shame there is hardly a reaction here so far Its another piece of pioneer work and proof of principle and concept Sangamo just dropped this TX200 update (CAR-Tregs in kidney transplant) and its exactly https://t.co/4nIH75waG2 This Car-Tregs data $SGMO shared"
X Link 2025-10-09T02:20Z [--] followers, [---] engagements

"$SGMO Where does Fabry fit into your calculus @SGurthy When it comes to Big Pharma its not that they dont see $SGMO s value its timing optics and validation. If I were a Big Pharma executive with a Martin Shkreli mindset Id be just as relaxed about recognizing value like this. Its part of the game. While the rule of @SGurthy When it comes to Big Pharma its not that they dont see $SGMO s value its timing optics and validation. If I were a Big Pharma executive with a Martin Shkreli mindset Id be just as relaxed about recognizing value like this. Its part of the game. While the rule of"
X Link 2025-10-16T20:55Z [--] followers, [----] engagements

"In requesting an additional [---] day period to cure the Nasdaq bid-price requirement Sangamo must explicitly notify their "intent to cure." I assume $SGMO cannot say they intend to run the ATM dry. Won't they have to submit a detailed plan that Nasdaq can verify or not"
X Link 2025-10-16T21:46Z [--] followers, [---] engagements

"@Franca_ole @SangamoTx @sandymacrae23 @JohnMarkels $SGMO Everything Sangamo will be out of cash in a few weeks. They are teetering on the edge of bankruptcy. Sangamo had a buy-out offer in [----] @$28/share - Sandy declined b/c he thought IVPR was the golden goose - it failed. #criminalmismanagement #clownshow"
X Link 2025-02-13T13:59Z [--] followers, [---] engagements

"@Franca_ole @SangamoTx @sandymacrae23 @JohnMarkels Seems Sangamo management are incapable of closing a Fabry partnership. Since they are almost out of cash and SGMO is now trading below $1 their negotiating position is about as bad as it can get. #clownshow #criminalmismanagement"
X Link 2025-02-25T15:26Z [--] followers, [---] engagements

"$SGMO @SangamoTx @sandymacrae23 @johnmarkels How long will the criminally negligent Sangamo EM keep up the Fabry multiple-interested-parties charade #NoFabryPartner #Fraud"
X Link 2025-10-08T16:18Z [--] followers, [----] engagements

"$CRSP market cap is 33x $SGMO market cap. Remember when Sandy called them a "boy band" That was funny right @sandymacrae23 @SangamoTx @JohnMarkels #NoFabryPartner #NoMoney #NoCredibilitly"
X Link 2025-10-21T14:16Z [--] followers, [---] engagements

"@meangenebio @Franca_ole The NHP data has been known for some time. Why change from [--] weeks to [--] weeks now"
X Link 2025-10-29T02:30Z [--] followers, [--] engagements

"$SGMO Though I find @BiotechAnalysst is consistently overly optimistic wrt Sangamo this does seem like the most likely reason for the trial update. Anyone else"
X Link 2025-10-29T18:11Z [--] followers, [----] engagements

"$SGMO Every quarter perma-bulls work themselves up into a tizzy trying to read something positive into the timing of the earnings release and Sangamo disappoints 98% of the time. But THIS time will be different right"
X Link 2025-10-30T22:36Z [--] followers, [---] engagements

"@Soeren_Berlin So you believe they have struck a deal with AZN but are not shouting it from the rooftops because AZN have said they want to announce the deal on their earnings release date"
X Link 2025-10-30T22:47Z [--] followers, [---] engagements

"@Soeren_Berlin @meangenebio Can you explain in simple terms why $SGMO investors should/ should not worry about read-thru from QURE's doubts about whether early data is sufficient for FDA approval"
X Link 2025-11-03T22:08Z [--] followers, [---] engagements

"$SGMO @sandmacrae23 True - money managers don't want to take this kind of risk but hedge funds will buy if they believe there is real upside. Nobody wants to buy with the constant threat of dilution overhead. They need to show they can bring in significant non-dilutive funding"
X Link 2025-11-05T17:15Z [--] followers, [----] engagements

"@BiotechAnalysst As usual your post is deceiving. The base price target is $2 but you highlight the upside $11 target. And you fail to post the Barclays report where Gina Wang finally capitulates and lowers her price target from $5 to $1 (though I find her capitulation bullish)"
X Link 2025-11-07T13:00Z [--] followers, [---] engagements

"@thecellengineer @meangenebio @ZinselmeyerB Interesting. At what point during partnership negotiations would you expect a potential partner to have data room access and why wouldn't they have that access now if Sangamo are in fact "in final stages of negotiation" Why would Sangamo postpone giving access"
X Link 2025-11-09T12:22Z [--] followers, [---] engagements

"@sandymacrae23 @johnmarkels @sangamotx Sandy sent this "please stick with us" email more than [--] months ago. How many shares have $SGMO issued via the ATM since then #NoFabryPartner #Fraud $SGMO @SangamoTx @sandymacrae23 @JohnMarkels Sangamo over and over communicate a non-dilutive funding event (ex. partnership) is close then within a short period hit shareholders with dilutive funding. This "stick with us" email soon may be Exhibit A in a shareholder lawsuit. https://t.co/MrhTEJTMkh $SGMO @SangamoTx @sandymacrae23 @JohnMarkels Sangamo over and over communicate a non-dilutive funding event"
X Link 2025-11-12T19:35Z [--] followers, [----] engagements

"@Soeren_Berlin @pencilvester999 @Franca_ole @Soeren_Berlin Still not worried about Sangamo finding cash"
X Link 2025-11-12T21:44Z [--] followers, [--] engagements

"@bduclaux @Soeren_Berlin @meangenebio @Franca_ole All stakeholders should like to understand whether this is plausible. Maybe some on this board could flesh out the details Could it be Sangamo have investors on stand-by in the event they go-it-alone & this is why they are moving everything forward despite not having cash"
X Link 2025-11-13T13:35Z [--] followers, [---] engagements

"$ENGN @meangenebio @Soeren_Berlin Hello. Any thoughts on enGene and their non-viral gene therapies"
X Link 2025-11-16T13:57Z [--] followers, [---] engagements

"@mehtamanal @sandymacrae23 $SGMO Lets assume Sandy has been negotiating with BPs who really dont want to cure Fabry. Which people/companies do want to cure Fabry and other genetic diseases You mentioned Mark Cuban. Who else Big Bio (Alnylam Vertex) other (Google DeepMind)@meangenebio"
X Link 2025-11-23T13:31Z [--] followers, [---] engagements

"$SGMO Here is ChatGPT's response to my question. $SGMO While we wait can someone explain why a specific gene therapy cannot be dosed with one AAV initially and a second/different AAV if re-dosing is desirable in future to avoid the immune response associated with re-dosing with the same AAV $SGMO While we wait can someone explain why a specific gene therapy cannot be dosed with one AAV initially and a second/different AAV if re-dosing is desirable in future to avoid the immune response associated with re-dosing with the same AAV"
X Link 2025-11-24T17:29Z [--] followers, [----] engagements

"$SGMO @Soeren_Berlin Does it concern you that it has been a year since Sandy said they were working on term sheets for a Fabry partnership and [--] months since he said they were in "final stages of negotiation" #Fraud @sandymacrae23 @JohnMarkels @SangamoTx $SGMO Seeing some speculation so let me clarify a few things: [--]. I have very little time to be online on X lately. And yes Im also annoyed by the anti-communication approach from management and the fact that theyre not using support where its needed. Im still fully here $SGMO Seeing some speculation so let me clarify a few things: [--]. I have"
X Link 2025-12-01T16:04Z [--] followers, [----] engagements

"@sandymacrae23 @johnmarkels @sangamotx All Sangamo news is bad news for $SGMO stockholders b/c most company news is negative and ALL positive news is immediately followed by dilution. Nothing matters until they show they can monetize something ANYTHING"
X Link 2025-12-02T15:51Z [--] followers, [---] engagements

"@sandymacrae23 @johnmarkels @SangamoTx @Soeren_Berlin I guess you are not worried that October came and went with no news on ST-503 dosing just like you are not worried that $SGMO have not partnered Fabry more than a year after saying they were putting together deal term sheets. https://t.co/jxqfos9iRm https://t.co/jxqfos9iRm"
X Link 2025-12-16T14:23Z [--] followers, [----] engagements

"$SGMO @sandymacrae23 @johnmarkels @sangamotx Novartis ended their partnership with Sangamo in June [----]. What is the point in posting and re-posting this mouse data from [----] $SGMO $SGMO"
X Link 2025-12-29T17:21Z [--] followers, [---] engagements

"$SGMO @sandymacrae23 @johnmarkels @sangamotx @prtj1 Sangamo close out the year with a big middle finger to shareholders. Let's see how long before they kick shareholders in the face with more dilution. Keep up the great work Sandy #NoFabryPartner #Fraud"
X Link 2025-12-31T21:37Z [--] followers, [---] engagements

"@Soeren_Berlin You were uber bullish on $SGMO when you published this report [--] months ago. Given Sangamo have not dosed the 1st patient and it seems there will be no related news any time soon what is your current view Are you still all-in on $SGMO @sandymacrae23 @sangamotx https://t.co/jxqfos9iRm https://t.co/jxqfos9iRm"
X Link 2026-01-12T16:37Z [--] followers, [----] engagements

"$SGMO @Franca_ole Which surrogate endpoints would allow for the reduction in primary outcome from [--] to [--] weeks What data did Sangamo need to show to support the reduction In particular the reduction of the primary outcome from [--] to [--] weeks seems spectacular to me.the first results should be available in mid-2026. If they deliver what the preclinical trials promise then $SGMO will go through the roof. And what is the reaction on the stock In particular the reduction of the primary outcome from [--] to [--] weeks seems spectacular to me.the first results should be available in mid-2026. If they"
X Link 2025-10-28T20:27Z [--] followers, [----] engagements

"$SGMO @GeneInvesting @meangenebio If the same data were released by a bio other than Sangamo (one w/ cash and strong management) would you be optimistic about this becoming a meaningful Fabry treatment or SOC We know management is a zero. What is the data on a scale of [--] to 10"
X Link 2026-02-03T22:03Z [--] followers, [---] engagements

"$SGMO Per the FDA. @GothamGirl_1 @meangenebio @Franca_ole Because you have to submit plans for mass scale manufacturing production and dosing with certain protocols that must be replicated without fail. It's expensive and labor intensive. That's why they want to find a partner. @GothamGirl_1 @meangenebio @Franca_ole Because you have to submit plans for mass scale manufacturing production and dosing with certain protocols that must be replicated without fail. It's expensive and labor intensive. That's why they want to find a partner"
X Link 2026-02-04T21:34Z [--] followers, [----] engagements

"@TheCryptoMaze $SGMO Agreed. Also the FDA keeps talking about making it easier to approve genetic medicines. Amending the BLA CMC requirements to accommodate small patient populations should be part of this effort"
X Link 2026-02-04T22:04Z [--] followers, [---] engagements

"$SGMO They are moving forward (small scale production) w/ Fabry w/out a partner. This explains the recent dilution. They recognize no one will pay close to what they believe it is worth (b/c Sangamo has no leverage). There may be more dilution but they will keep all the revenue"
X Link 2026-02-07T18:52Z [--] followers, [----] engagements

"@TristatePhil I have been consistently positive about the science/ tech and negative about the clown-show management. Management should have realized sooner that BP "potential partners' have been stringing them along. Better late than never"
X Link 2026-02-07T21:11Z [--] followers, [---] engagements

"$SGMO @ZinselmeyerB has some interesting thoughts on commercialization. I cannot reply to him directly because he has blocked me for my brutally honest comments about Sangamo's executive management. I am guessing it is only recently that Sangamo realize they do not need BP. @GothamGirl_1 It is quite conceivable that self-marketing in the US market will prove to be the most valuable approach for $SGMO in the long term. The majority of the economic potential of Fabry gene therapy lies in the US and a cumbersome big pharma sales structure is not necessary @GothamGirl_1 It is quite conceivable"
X Link 2026-02-08T01:59Z [--] followers, [----] engagements

"$SGMO Regarding the temporary Communications Manager position Melinda Hutcheon Senior Director Corporate Communications left in January. From Stocktwits"
X Link 2026-02-11T00:27Z [--] followers, [----] engagements

"@Corona_N_Lyme It was probably difficult to field all those angry emails calls and vms from shareholders"
X Link 2026-02-11T18:27Z [--] followers, [--] engagements

"@SchoolyardPS7 I dont believe that no BP wants ST-920 - they dont want to pay what Sangamo are asking. It is a game of chicken. If Sangamos BLA is approved or if a reasonable bid emerges then BP and Big Bio will step up"
X Link 2026-02-14T17:49Z [--] followers, [---] engagements

"@SchoolyardPS7 Are you saying you think they would have sold Fabry for $50mm or partnered for $50mm upfront + milestones and royalties"
X Link 2026-02-15T00:14Z [--] followers, [--] engagements

"$SGMO Some here have said Sangamo could not go-it-alone with Fabry but it seems they intend to do just that. So how do they get from here to commercialization without a partner And how do they move forward with the pain trial And Prion"
X Link 2026-02-04T01:52Z [--] followers, [---] engagements

"@ZinselmeyerB @BAMBossie81 @SangamoTx $SGMO Big pharma do not want Sangamo to succeed. Sangamo should be talking to big biotech - Vertex Regeneron Alnylam - or large biotech investors - Alphabet The Gates Foundation Mark Cuban - before it is too late. @sandymacrae23 @SangamoTx"
X Link 2026-02-12T13:42Z [--] followers, [---] engagements

"Everyone should block @BiotechAnalysst He is the same idiot who posts every time a hedge fund increases their $SGMO holdings but he never posts about the decreases. There is no evidence to support his post from today"
X Link 2026-02-12T17:33Z [--] followers, [----] engagements

"CRSP is successful in large part because they partnered with Vertex a Big Biotech (not Big Pharma) committed to curing disease. $SGMO need to partner with Big Bio if they want to survive. Big Pharma want Sangamo to fail. @sandymacrae23 @JohnMarkels @SangamoTx"
X Link 2026-02-15T15:25Z [--] followers, [---] engagements

"It is quite conceivable that self-marketing in the US market will prove to be the most valuable approach for $SGMO in the long term. The majority of the economic potential of Fabry gene therapy lies in the US and a cumbersome big pharma sales structure is not necessary especially for a rare highly specialized indication such as Fabry. A focused medical and sales team may be sufficient to effectively address the market. The key point here is that the true value of ST-920 will probably only become fully apparent after approval and with the first real-world data. If Sangamo were to conclude a"
X Link 2026-02-07T22:09Z [----] followers, [----] engagements

"$SGMO QURE up 12% despite falling short of Sangamo's data. It is difficult for the market to have any faith in Sangamo's clown-show management after that inexplicably-dilutive equity raise the same day they released great data this week. @sandymacrae23 @SangamoTx #clownshow $SGMO $QURE Head to Head AMT-191 data falls short [--] or [--] of [--] patients discontinued ERT which is significantly worse than ST-920 where all [--] dosed patients have come off ERT ERT withdrawal in the uniQure study appears to be dose-dependent with limited durability data and $SGMO $QURE Head to Head AMT-191 data falls short"
X Link 2026-02-06T14:47Z [--] followers, [----] engagements

"$SGMO $QURE Head to Head AMT-191 data falls short [--] or [--] of [--] patients discontinued ERT which is significantly worse than ST-920 where all [--] dosed patients have come off ERT ERT withdrawal in the uniQure study appears to be dose-dependent with limited durability data and potential safety tradeoffs at higher doses While uniQure reports supraphysiologic -Gal A enzyme activity up to 223-fold above normal this is not necessarily beneficial and could pose regulatory and biological risks especially since clinical benefit does not scale linearly with enzyme levels beyond a certain threshold Most"
X Link 2026-02-06T14:14Z [---] followers, [----] engagements

"@GothamGirl_1 @meangenebio @Franca_ole Because you have to submit plans for mass scale manufacturing production and dosing with certain protocols that must be replicated without fail. It's expensive and labor intensive. That's why they want to find a partner"
X Link 2026-02-04T21:26Z [---] followers, [----] engagements

"$SGMO @meangenebio @Franca_ole This seems plausible. Why couldn't Sangamo commercialize ST-920 on a manageable scale on their own How would that change the BLA submission if at all"
X Link 2026-02-04T19:11Z [--] followers, [---] engagements

"$SGMO do not care about read: despise shareholders. Accept that this is true. Sangamo believe they are worth much more than anyone is willing to pay and de-listing is approaching. Why not go private What price would they need to pay to avoid shareholder lawsuits"
X Link 2026-02-04T18:49Z [--] followers, [---] engagements

"$SGMO Today Sangamo publicly admitted there is no imminent or close Fabry partner. Maybe @sandymacrae23 will finally resign in shame. He should be in jail. @SangamoTx"
X Link 2026-02-03T20:14Z [--] followers, [---] engagements

"$SGMO Could it be the investor(s) who bought this offering made it conditional on pricing before the data is released What was the alternative funding option for Sangamo even with good data Continue to hit the ATM There is no imminent partner. Will they go it alone"
X Link 2026-02-03T19:39Z [--] followers, [---] engagements

"$SGMO The criminally negligent CEO Sandy: 484-919-2714 and the do-nothing chairwoman H. Stewart Parker: 206-601-1211. Good luck"
X Link 2026-01-28T19:17Z [--] followers, [----] engagements

"$SGMO Not true. The position is still listed on Sangamo's web site. @BAMBossie81 $SGMO so the temporary senior manager corporate communications position is no longer posted. That was fast if filled. Lets see what is the first piece of PR he/she produces for our pleasure. @BAMBossie81 $SGMO so the temporary senior manager corporate communications position is no longer posted. That was fast if filled. Lets see what is the first piece of PR he/she produces for our pleasure"
X Link 2026-01-28T18:15Z [--] followers, [----] engagements

"@BAMBossie81 $SGMO so the temporary senior manager corporate communications position is no longer posted. That was fast if filled. Lets see what is the first piece of PR he/she produces for our pleasure"
X Link 2026-01-27T22:01Z [---] followers, [----] engagements

"$SGMO Astounding shareholder abuse here. I can't waste anymore energy trying to bring attention to the criminal mismanagement and fraud. Ping me when the inevitable shareholder class action lawsuits begin - I am happy to help gather evidence. @sandymacrae23 @SangamoTx #Fraud"
X Link 2026-01-13T15:27Z [--] followers, [----] engagements

"$SGMO Wasn't the original plan to dose the 1st patient last October December 2nd you stated you are preparing to dose the 1st patient. You still have not dosed the 1st patient. Will this take [--] years like your mythical Fabry partnership negotiations @sandymacrae23 @SangamoTx Today we are pleased to announce that the FDA has granted Fast Track Designation to ST-503 an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN) a type of chronic neuropathic pain. News Release: https://t.co/zjm4QyDzKd https://t.co/jlP2hUCFXq Today we are pleased"
X Link 2026-01-12T15:43Z [--] followers, [----] engagements

"Today we are pleased to announce that the FDA has granted Fast Track Designation to ST-503 an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN) a type of chronic neuropathic pain. News Release: https://bit.ly/4pMztpl https://bit.ly/4pMztpl"
X Link 2025-12-02T13:16Z [----] followers, 15.9K engagements

"NTLA directors are not afraid to buy shares. The idea that Sangamo management and BOD members cannot buy shares b/c they are in negotiations is preposterous. NTLA likely have many more current partnership negotiations than $SGMO do. @sandymacrae23 @JohnMarkels @SangamoTx #Fraud"
X Link 2026-01-08T18:06Z [--] followers, [---] engagements

"$SGMO Now [--] months - how are those final Fabry partnership negotiations going Sandy @sandymacrae23 @JohnMarkels @SangamoTx #NoFabryPartner #Fraud $SGMO @sandymacrae23 @johnmarkels @sangamotx Now [--] months since Sandy said Sangamo are in "final stages of Fabry negotiations." #NoFabryPartner #Fraud #ClownShow https://t.co/9EyHXBTFG2 $SGMO @sandymacrae23 @johnmarkels @sangamotx Now [--] months since Sandy said Sangamo are in "final stages of Fabry negotiations." #NoFabryPartner #Fraud #ClownShow https://t.co/9EyHXBTFG2"
X Link 2026-01-08T13:20Z [--] followers, [---] engagements

"$SGMO @sandymacrae23 @johnmarkels @sangamotx Now [--] months since Sandy said Sangamo are in "final stages of Fabry negotiations." #NoFabryPartner #Fraud #ClownShow"
X Link 2025-12-16T13:56Z [--] followers, [----] engagements

"$SGMO Sangamo shareholder abuse has been astounding. To create a timeline and aid with the inevitable class action lawsuits use this thread to post/collect evidence of Sandy's misleading statements (include emails/ transcripts) & dilution timing. @sandymacrae23 @SangamoTx #Fraud"
X Link 2026-01-07T16:12Z [--] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing